A couple added points for drug company educational reasons.  May help someone thinking about a drug company investment long after RAZF is gone:

 

(1)  The affected patient is a US woman who developed this after 18 Tysabri treatments (on it for a while-thats been the MO here on these events) and her condition was monitored, caught, she is being treated, and we hope she will recover from this brain condition (PML). Bet she still wants Tysabri if cured of PML!  PML is treatable and if monitored properly can be taken care of.

 

(2)  Regarding WYE and ELN trying to start these Alzheimer studies too fast, go back to Kutz's posts in Post3 (Item listed #2) and Post 4.  Maybe these companies should hire me to run their programs?    

 

I know why they did it-it was cutting corners because of multiple companies current development of many Alzheimer drugs and the "race" that is in progress in this market. Its a big one!  But when marketing decisions take precident over good science decisions, this is what happens in pharma companies and their PPS and we ultimately suffers.   

 

Happens all the time.  I have trained more doctors (smart ones) often recommended by marketing departments because they buy large numbers of drugs from a company and yet they have absolutely no understanding how to do regulated clinical research studies. its different than just treating patients.  They are smart, but not always when it comes to everything!

 

This adds to the risk in developing drugs and investing in them!  Its a mine field to sort through. Why many avoid drug investment. 

 

Kutz